用于肝细胞癌免疫治疗的α-甲胎蛋白特异性T细胞受体的鉴定
本研究利用慢病毒载体和肽免疫在HLA-A2转基因AAD小鼠中鉴定出识别AFP158表位的CD8 T细胞,并从中获得三对小鼠TCR基因。表达这些TCR的人T细胞可特异性结合HLA-A2/AFP158四聚体、识别并杀伤HLA-A2+ AFP+ HepG2细胞,且对正常原代肝细胞无明显毒性;过继转移可清除NSG小鼠的HepG2肿瘤。
要点
- 在HLA-A2转基因AAD小鼠中鉴定出识别AFP158表位的CD8 T细胞。
- 从5个杂交瘤中获得3对配对TCR基因,可重定向人T细胞结合HLA-A2/AFP158四聚体。
- AFP特异性TCR-T细胞可特异性杀伤HLA-A2+ AFP+ HepG2细胞,对正常原代肝细胞无明显毒性。
核心结论
- 已鉴定出AFP特异性小鼠TCR基因,可重定向人T细胞特异性识别和杀伤肝细胞癌肿瘤细胞,AFP158特异性TCR有望用于改造患者自体T细胞以治疗肝细胞癌。
研究设计与样本
- 利用慢病毒载体和肽免疫在HLA-A2转基因AAD小鼠中鉴定AFP158特异性CD8 T细胞,并建立T细胞杂交瘤克隆以获取配对TCR基因。
- 在免疫缺陷NSG小鼠中进行过继转移实验,并在体外用原代正常人肝细胞评估毒性。
主要发现
- AFP158特异性小鼠CD8 T细胞过继转移可清除NSG小鼠中直径达2 cm的HepG2肿瘤异种移植瘤。
- 从5个杂交瘤中鉴定出3对配对TCR基因,表达小鼠TCR基因可重定向原代人T细胞结合HLA-A2/AFP158四聚体。
- TCR基因工程人T细胞可特异性识别HLA-A2+ AFP+ HepG2肿瘤细胞并产生效应细胞因子。
- TCR-T细胞可在体外特异性杀伤HLA-A2+ AFP+ HepG2肿瘤细胞,对正常原代肝细胞无明显毒性。
- AFP特异性TCR-T细胞过继转移可清除NSG小鼠中的HepG2肿瘤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Hepatocellular carcinoma (HCC) is the major form of liver cancer for which there is no effective therapy. Genetic modification with T-cell receptors (TCRs) specific for HCC-associated antigens, such as α-fetoprotein (AFP), can potentially redirect human T cells to specifically recognize and kill HCC tumor cells to achieve antitumor effects. In this study, using lentivector and peptide immunization, we identified a population of cluster of differentiation 8 (CD8) T cells in human leukocyte antigen (HLA)-A2 transgenic AAD mice that recognized AFP158 epitope on human HCC cells. Adoptive transfer of the AFP158 -specific mouse CD8 T cells eradicated HepG2 tumor xenografts as large as 2 cm in diameter in immunocompromised nonobese diabetic severe combined immunodeficient gamma knockout (NSG) mice. We then established T-cell hybridoma clones from the AFP158 -specific mouse CD8 T cells and identified three sets of paired TCR genes out of five hybridomas. Expression of the murine TCR genes redirected primary human T cells to bind HLA-A2/AFP158 tetramer. TCR gene-engineered human T (TCR-T) cells also specifically recognized HLA-A2+ AFP+ HepG2 HCC tumor cells and produced effector cytokines. Importantly, the TCR-T cells could specifically kill HLA-A2+ AFP+ HepG2 tumor cells without significant toxicity to normal primary hepatocytes in vitro. Adoptive transfer of the AFP-specific TCR-T cells could eradicate HepG2 tumors in NSG mice. CONCLUSION: We have identified AFP-specific murine TCR genes that can redirect human T cells to specifically recognize and kill HCC tumor cells, and those AFP158 -specific TCRs have a great potential to engineer a patient's autologous T cells to treat HCC tumors. (Hepatology 2018).
引用
- Zhu W, Peng Y, Wang L, et al. Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy. Hepatology. 2018. PMID: 29443377. doi:10.1002/hep.29844
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。